| Georgis Patsias, MD | |
|
3347 State Road 7, Suite 101, Wellington, FL 33449-8095 | |
| (561) 790-2111 | |
| (561) 790-0348 |
| Full Name | Georgis Patsias |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 43 Years |
| Location | 3347 State Road 7, Wellington, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942285390 | NPI | - | NPPES |
| 373720900 | Medicaid | FL | |
| P01596409 | Other | FL | RR MEDICARE |
| P102736 | Other | FL | OPTIMUN |
| P107179 | Other | FL | FREEDOM |
| 1249251 | Other | FL | WELLCARE |
| 18997 | Other | FL | BCBS |
| 3615094 | Other | FL | KEYS PHA - CIGNA |
| 1004500 | Other | FL | CAREPLUS |
| 4311 | Other | FL | DIMENSIONS |
| 5500033 | Other | FL | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME0049282 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellington Regional Medical Center Llc | Wellington, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Genesiscare Usa Of Florida Llc | 9830082882 | 263 |
News Archive
Research carried out by veterinary scientists at the Royal Veterinary College reveals that deer antler regeneration may use stem cells and involves similar mechanisms to those used in limb development.
Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.
One new SARS-CoV-2 variant of concern, called 202012/01, started to spread in England in late October. A new study published on the pre-print server medRxiv found that 60 percent of daily COVID-19 cases screened by the Alderley Park Lighthouse Labs were tied to 202012/01, also known as lineage B.1.1.7 or 20B/501Y.V1. This suggests a rapid spread of the new variant across the country.
This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced that it closed private offerings in December and October 2010 pursuant to which it entered into definitive agreements with accredited investors to purchase a total of 845,000 shares of the Genesis Biopharma common stock for a purchase price of $1.00 per share.
› Verified 7 days ago
| Entity Name | Genesiscare Usa Of Florida Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134109747 PECOS PAC ID: 9830082882 Enrollment ID: O20040204000663 |
News Archive
Research carried out by veterinary scientists at the Royal Veterinary College reveals that deer antler regeneration may use stem cells and involves similar mechanisms to those used in limb development.
Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.
One new SARS-CoV-2 variant of concern, called 202012/01, started to spread in England in late October. A new study published on the pre-print server medRxiv found that 60 percent of daily COVID-19 cases screened by the Alderley Park Lighthouse Labs were tied to 202012/01, also known as lineage B.1.1.7 or 20B/501Y.V1. This suggests a rapid spread of the new variant across the country.
This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced that it closed private offerings in December and October 2010 pursuant to which it entered into definitive agreements with accredited investors to purchase a total of 845,000 shares of the Genesis Biopharma common stock for a purchase price of $1.00 per share.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Georgis Patsias, MD 2234 Colonial Blvd, Attn: Payer Contracting & Relations Dept., Fort Myers, FL 33907-1412 Ph: (239) 931-7342 | Georgis Patsias, MD 3347 State Road 7, Suite 101, Wellington, FL 33449-8095 Ph: (561) 790-2111 |
News Archive
Research carried out by veterinary scientists at the Royal Veterinary College reveals that deer antler regeneration may use stem cells and involves similar mechanisms to those used in limb development.
Joseph F. Finn, Jr., C.P.A. , announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction.
One new SARS-CoV-2 variant of concern, called 202012/01, started to spread in England in late October. A new study published on the pre-print server medRxiv found that 60 percent of daily COVID-19 cases screened by the Alderley Park Lighthouse Labs were tied to 202012/01, also known as lineage B.1.1.7 or 20B/501Y.V1. This suggests a rapid spread of the new variant across the country.
This year's prestigious Canadian Prix Galien for Innovative Product Award has been presented to Esbriet (pirfenidone), a medicine used to treat idiopathic pulmonary fibrosis (IPF). It is the only medication approved in Canada with a specific IPF indication and is approved for mild to moderate IPF in adults.
Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced that it closed private offerings in December and October 2010 pursuant to which it entered into definitive agreements with accredited investors to purchase a total of 845,000 shares of the Genesis Biopharma common stock for a purchase price of $1.00 per share.
› Verified 7 days ago
Dr. Rafael Roberto Lopez, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3347 State Road 7, Suite 101, Wellington, FL 33449 Phone: 561-790-2111 Fax: 561-790-0893 | |
Dr. Edward Rene Becker, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3347 State Road 7, Suite 101, Wellington, FL 33449 Phone: 561-790-2111 Fax: 561-790-0893 | |
Dr. Damian Portela, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3347 State Road 7, Suite 101, Wellington, FL 33449 Phone: 561-790-2111 Fax: 561-296-0436 | |
Jerry Herbert Singer, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 10115 Forest Hill Blvd, Suite 100, Wellington, FL 33414 Phone: 561-333-1118 Fax: 561-333-2228 | |
Hugo Hernandez, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 10111 W Forest Hill Blvd, #200, Wellington, FL 33414 Phone: 561-798-0341 Fax: 561-798-1304 | |
Fred Muhletaler, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3347 State Road 7, Suite 101, Wellington, FL 33449 Phone: 561-790-2111 Fax: 561-296-0436 | |
Dr. Steven Joseph Varady, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 3347 State Road 7, Suite 101, Wellington, FL 33449 Phone: 561-790-2111 Fax: 561-790-0893 |